Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2CNS 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 73Myelodysplastic Syndromes 34Leukemia, Lymphocytic, Chronic, B-Cell 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Leukemia, Biphenotypic, Acute 17Hematologic Neoplasms 14Burkitt Lymphoma 14Myeloproliferative Disorders 13Leukemia, Myelomonocytic, Chronic 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Non-Hodgkin 7Myelodysplastic-Myeloproliferative Diseases 6Multiple Myeloma 6Lymphoma 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Primary Myelofibrosis 5Lymphoma, Large B-Cell, Diffuse 5Hodgkin Disease 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Prostatic Neoplasms 3Neoplasm Metastasis 3Melanoma 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma, B-Cell 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Hairy Cell 3GATA2 Deficiency 3

Interventions

Nivolumab 2Specimen Handling 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Turcot syndrome × Specimen Handling × Other hematologic neoplasm × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡